EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Differential Nasal Recolonization and Microbial Profiles in Chronic Rhinosinusitis With Nasal Polyps Patients After Endoscopic Sinus Surgery or Dupilumab Treatment: A Prospective Observational Study

Antonino Maniaci iD, Gaia Vertillo Aluisio iD, Stefania Stefani iD, Salvatore Cocuzza iD, Jerome Rene Lechien iD, Thomas Radulesco iD, Justin Michel iD, Maria Santagati iD, Ignazio La Mantia iD

Clinical Otolaryngology · 2025

DOI: 10.1111/coa.14246 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Otolaryngology, 2025. Verfasst von Antonino Maniaci und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Enna "Kore", Enna, Italy. Hauptthemen laut MEDLINE: Nasal Polyps, Sinusitis, Rhinitis, Endoscopy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: EU Next Generation funding, MUR PNRR Extended Partnership initiative on Emerging Infectious Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The role of microbial profiles in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) pathogenesis is increasingly recognised, with microbial imbalances perpetuating inflammation. We performed this study to associate the different nasal microbiological profile changes with the response to surgical or monoclonal treatment.

Methods

This prospective observational study evaluated changes in the nasal microbial profiles of 44 patients (22 dupilumab, 22 surgery) over 6 months. Clinical assessments were performed at baseline and follow‐ups, including Sino‐Nasal Outcome Test‐22 (SNOT‐22) scores and Sniffin Sticks‐Identification (SS‐I) olfactory testing. Microbial profiling of nasal swabs was carried out by microbial culture and subsequent molecular identification by Polymerase chain reaction (PCR) and sequencing.

Results

Baseline characteristics of 44 patients (22 dupilumab, 22 surgery) enrolled in this study were similar between groups. In the dupilumab group, Staphylococcus epidermidis prevalence rose from 37.03% to 59.25%, while Pseudomonas aeruginosa was eradicated. Moreover, dupilumab stabilised Staphylococcus aureus at 63.64%, while its prevalence increased in the surgery group (from 22.72% to 50%). When bacterial groups were associated with clinical scores, P. aeruginosa carriers had worse SNOT‐22 (21.00 ± 1.41) and SS‐I (5.50 ± 0.71) scores. Instead, S. epidermidis ‐colonised patients exhibited significantly lower mean SNOT‐22 (15.39 ± 8.54) and greater SS‐I scores (8.39 ± 3.77). The best outcomes were found in the subgroup of S. epidermidis carriers undergoing the dupilumab treatment.

Conclusion

The two treatments modulated the microbial profiles differently, and, most importantly, clinical responses might depend on the association between treatment and the dominant bacterial species colonising the nasal cavity. Further investigation into microbial‐restorative strategies could enhance outcomes for better treatment of CRS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal PolypsSinusitisRhinitisEndoscopyAntibodies, Monoclonal, HumanizedHumansMaleProspective StudiesFemaleChronic DiseaseMiddle AgedAdultAgedRhinosinusitis

Stichwörter der Autor:innen

Pseudomonas aeruginosaStaphylococcus aureusCRSwNPDupilumabnasal microbiome

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medicine and Surgery, University of Enna "Kore", Enna, Italy.
  • Rhynology Study Group of the Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), Paris, France.
  • Section of Microbiology, Department of Biomedical and Biotechnological Sciences (BIOMETEC), Microbiologia Medica Molecolare e Antibiotico Resistenza (MMARLab), University of Catania, Catania, Italy.
  • Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia" ENT Section, University of Catania, Catania, Italy.
  • Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.
  • ENT Surgeon, Department of Oto-Rhino-Laryngology Head and Neck Surgery, La Conception University Hospital, University of Aix-Marseille, Marseille, France.

ORCID-Profile: Antonino Maniaci, Gaia Vertillo Aluisio, Stefania Stefani, Salvatore Cocuzza, Jerome Rene Lechien, Thomas Radulesco, Justin Michel, Maria Santagati, Ignazio La Mantia

Förderung

  • EU Next Generation funding
  • MUR PNRR Extended Partnership initiative on Emerging Infectious Disease

Zitieren

APA

Maniaci, A., Vertillo Aluisio, G., Stefani, S., Cocuzza, S., Lechien, J. R., Radulesco, T., Michel, J., Santagati, M., & La Mantia, I. (2025). Differential Nasal Recolonization and Microbial Profiles in Chronic Rhinosinusitis With Nasal Polyps Patients After Endoscopic Sinus Surgery or Dupilumab Treatment: A Prospective Observational Study. Clinical Otolaryngology. https://doi.org/10.1111/coa.14246

Vancouver

Maniaci A, Vertillo Aluisio G, Stefani S, Cocuzza S, Lechien JR, Radulesco T, et al. Differential Nasal Recolonization and Microbial Profiles in Chronic Rhinosinusitis With Nasal Polyps Patients After Endoscopic Sinus Surgery or Dupilumab Treatment: A Prospective Observational Study. Clinical Otolaryngology. 2025. doi:10.1111/coa.14246

BibTeX
@article{Maniaci2025,
  author = {Maniaci, Antonino and Vertillo Aluisio, Gaia and Stefani, Stefania and Cocuzza, Salvatore and Lechien, Jerome Rene and Radulesco, Thomas and Michel, Justin and Santagati, Maria and La Mantia, Ignazio},
  title = {Differential Nasal Recolonization and Microbial Profiles in Chronic Rhinosinusitis With Nasal Polyps Patients After Endoscopic Sinus Surgery or Dupilumab Treatment: A Prospective Observational Study},
  journal = {Clinical Otolaryngology},
  year = {2025},
  doi = {10.1111/coa.14246}
}
Kostenlos starten →